JAGX - Jaguar Health, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1711
+0.0021 (+1.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.1690
Open0.1721
Bid0.1711 x 1300
Ask0.1950 x 2900
Day's Range0.1701 - 0.1800
52 Week Range0.1150 - 3.2000
Volume3,284,457
Avg. Volume8,177,126
Market Cap17.931M
Beta (3Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-1.6050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • ACCESSWIRE2 days ago

    Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders

    All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / May 24,2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing ...

  • ACCESSWIRE2 days ago

    Jaguar Health, Inc. Reports 2019 First Quarter Financial Results

    SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported first quarter 2019 results and issued the following highlights.

  • ACCESSWIRElast month

    Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief

    SAN FRANCISCO, CA / ACCESSWIRE / April 25, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably ...

  • ACCESSWIRE2 months ago

    Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results

    SAN FRANCISCO, CA / ACCESSWIRE / April 10, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported fourth quarter 2018 results and issued the following highlights. Total Mytesi prescription volume, which is the combination of new prescriptions and refills, as reported by IQVIA, grew 20% in the fourth quarter of 2018 versus the prior quarter, and increased 94% over the fourth quarter of 2017.

  • ACCESSWIRE2 months ago

    Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi

    SAN FRANSISCO, CA / ACCESSWIRE / April 2, 2019 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, issued the following updates today regarding the Company's March 28, 2019 meeting with the U.S. Food & Drug Administration (FDA) to review the protocol for Napo's planned Phase 3 clinical trial in cancer subjects to evaluate the effects of Mytesi® (crofelemer) in prevention and/or relief of cancer therapy-related diarrhea (CTD). Participants in the meeting, which was with the FDA's Division of Gastroenterology and Inborn Errors Products, included Pravin Chaturvedi, Ph.D., Napo's/Jaguar's Chairman of the Scientific Advisory Board (SAB) and Acting Chief Scientific Officer, regulatory affairs, medical safety monitoring, and biostatistics specialists, and academic key opinion leaders (KOLs)/SAB members from leading oncology treatment institutions, one of whom will serve as the Principal Investigator (PI) for the Company's planned trial.

  • ACCESSWIRE2 months ago

    Jaguar Health, Pipeline Review and Progress

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Jaguar Health, Inc. (JAGX), is a commercial stage natural-products pharmaceuticals company that focuses on developing gastrointestinal products for human prescription use and animals worldwide. Mytesi® (crofelemer), is a product of Jaguar's wholly-owned subsidiary Napo Pharmaceuticals, is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

  • ACCESSWIRE2 months ago

    Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi

    SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, ...

  • ACCESSWIRE2 months ago

    Four Biotech Stocks Setting The Standard On Wednesday

    CORAL GABLES, FL/ ACCESSWIRE / March 27, 2019 / The future of the biotech stock is predicated on the belief that the biotech sector is aptly prepared to develop innovative treatment options for patients in need. Through the use of machine learning, data analytics, genome sequencing, and other biotechnological advancements, companies in the biotech sector are working hard to improve the quality of life for consumers. Premier Health Group (PHGRF) (PHGI), Amyris Inc (AMRS), Jaguar Health Inc (JAGX), and AVEO Pharmaceuticals Inc (AVEO) are 4 healthcare companies making biotech companies making moves on Wednesday.

  • ACCESSWIRE2 months ago

    Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs

    SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2019 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has completed the filing with the U.S. Food & Drug Administration's Center for Veterinary Medicine (CVM) of the Chemistry, Manufacturing, and Controls (CMC) Technical Section in support of the Company's application for conditional approval of Canalevia™ (crofelemer delayed-release tablets) for treatment of chemotherapy-induced diarrhea (CID) in dogs. Canalevia™, Jaguar's lead veterinary drug product candidate, is a canine-specific oral formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree, which is sustainably harvested.

  • ACCESSWIRE2 months ago

    Four Healthcare Stocks Heating Up On Monday

    Whereas other sectors may cut corners or decrease quality in the name of revenue, healthcare companies do not have this luxury. As consumers, we expect the healthcare industry to create products and treatments to help us feel better and to invest in future technologies so that medical professionals can assist their patients in preventive medicine, not just reactive care. The healthcare industry has demonstrated in the first few months of 2019 that these expectations are more than fair, and if companies in the sector continue to prove their aptitude for helping patients, this may catalyze investor interest in the future.

  • ACCESSWIRE3 months ago

    Jaguar Health, Inc. Reports Voting Results from February 28, 2019 Special Meeting of Stockholders

    All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing ...

  • ACCESSWIRE3 months ago

    Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019

    SAN FRANCISCO, CA / ACCESSWIRE / February 25, 2019 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that its Special Meeting of Stockholders scheduled for February 25, 2019 (the "Special Meeting") was adjourned to achieve a quorum on the proposals set forth in Jaguar's definitive proxy statement on Schedule 14A, which was filed with the Securities and Exchange Commission (SEC) on January 18, 2019. The Special Meeting has been adjourned to 8:30 a.m. Pacific Standard Time/11:30 a.m. Eastern Standard Time on Thursday, February 28, 2019, at the offices of the Company at 201 Mission Street, Suite 2375, San Francisco, CA 94105.

  • What Kind Of Shareholders Own Jaguar Health, Inc. (NASDAQ:JAGX)?
    Simply Wall St.3 months ago

    What Kind Of Shareholders Own Jaguar Health, Inc. (NASDAQ:JAGX)?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Jaguar Health, Inc. (NASDAQ:JAGX) should be awareRead More...

  • ACCESSWIRE4 months ago

    With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product

    SAN FRANCISCO, CA / ACCESSWIRE / January 24, 2019 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Mytesi® (crofelemer) has been added to the formulary for Florida's AIDS Drug Assistance Program (ADAP). As a result of this addition, based on data from healthcare research firm Decision Resource Group, approximately 86% of ADAP-eligible US lives now have access to Mytesi, Jaguar's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

  • ACCESSWIRE4 months ago

    Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale

    SAN FRANCISCO, CA / ACCESSWIRE / January 22, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably ...

  • ACCESSWIRE5 months ago

    Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes

    SAN FRANCISCO, CA / ACCESSWIRE / January 9, 2019 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that a leading equine facility has placed the first order for the first-generation of Equilevia™, the Company's non-prescription, personalized, premium product for total gut health in high-performance equine athletes. As is common practice in the world of horse racing, the identity of the facility is not being disclosed. Equilevia contains ingredients isolated and purified from the medicinal Croton lechleri tree, which is sustainably harvested from the rainforest.

  • ACCESSWIRE5 months ago

    Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates

    SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced commercial sales updates today for the fourth quarter ended December 31, 2018.

  • ACCESSWIRE5 months ago

    Jaguar Health to Present at Biotech Showcase 2019 in San Francisco

    SAN FRANCISCO, CA / ACCESSWIRE / January 3, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Lisa Conte, Jaguar's president and chief executive officer, will present at the annual Biotech Showcase™ conference to be held in San Francisco, California on January 7 - 9, 2019. Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

  • ACCESSWIRE5 months ago

    Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance

    SAN FRANCISCO, CA / ACCESSWIRE / January 2, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, ...

  • ACCESSWIRE6 months ago

    Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer

    SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2018 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it has engaged T.R. Winston & Company, LLC (''T.R. Winston'') to provide strategic advice with respect to collaboration, licensing and development activities in support of Mytesi® and crofelemer. Mytesi is FDA-approved for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS who are on antiretroviral therapy.

  • ACCESSWIRE6 months ago

    Jaguar Health, Inc. Reports Third-Quarter 2018 Results

    SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported third quarter 2018 results and issued the following highlights. Mytesi Net Product Revenue: Mytesi gross sales in the third quarter of 2018 were approximately $1.6 million, and Mytesi net sales were approximately $1.1 million, an increase of 242% and 154% of gross and net sales, respectively, over the third quarter of 2017.

  • ACCESSWIRE6 months ago

    Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th

    Company to Host Conference Call Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to Review Q3 Results and Provide Updates Regarding Mytesi ® Commercial, Educational & Product Development Activities ...

  • ACCESSWIRE7 months ago

    The Brilliance Behind a Global Operator of Crypto Exchanges BitMax: Understanding the Trans-Fee Mining Model

    NEW YORK, NY / ACCESSWIRE / October 29, 2018 / As the demand for digital and crypto-assets grows, the long-term success of trading platforms is dependent on several factors including architecture design, ...

  • ACCESSWIRE7 months ago

    Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th

    SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it expects to file its third-quarter 2018 financial results on Wednesday, November 14, 2018 on Form 10-Q with the U.S. Securities and Exchange Commission. The Company will host a conference call on Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to discuss third-quarter results as well as current and planned commercial, educational and product development activities related to Mytesi (crofelemer), Jaguar's first-in-class, FDA-approved anti-secretory human prescription drug.

  • ACCESSWIRE7 months ago

    Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida

    SAN FRANCISCO, CA / ACCESSWIRE / October 24, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, ...